UBS cuts Epiroc to “sell,” sees 17% downside as valuation "gone too far"

Investing.com Gold reports: UBS cuts Epiroc to “sell,” sees 17% downside as valuation "gone too far". Full body text was unavailable at ingest time, so this brief is based on headline context.